Antiparasitic drug could be new treatment for brain tumours
New findings could help to extend the lives of patients suffering from one of the most common types of brain tumours - low-grade glioma.
List view / Grid view
News
Polyphor receives CHF 40 million private financing for antibiotic research
Polyphor Ltd, a clinical stage, privately held Swiss specialty pharma company focused on the development of macrocycle drugs addressing antibiotic resistance and respiratory diseases, has completed a CHF 40 million private placement. Exisiting Polyphor investors contributed to 98% of the financing.
New potential treatment for aggressive brain cancer in children
Using state-of-the-art gene editing technology, scientists have discovered a promising target to treat atypical teratoid/rhabdoid tumour (AT/RT) - a highly aggressive and therapy resistant brain tumour that mostly occurs in infants.
Premature cell differentiation leads to disorders in pancreatic development
Neonatal diabetes mellitus (NDM), or diabetes among infants less than six months of age, is a rare form of diabetes caused by a mutation in genes crusial to the development or function of beta cells. In about half of such cases, the disease becomes permanent (PNDM). Mutations in more than…
BenevolentAI to partner with medical research charity MRC technology
BenevolentAI, a British artificial intelligence company, has partnered with MRC Technology (MRCT), a medical research charity, to explore drug discovery initiatives in the field of small molecules and antibodies.
Tuberculosis: Researchers uncover how bacteria burst our cells
Scientists unveil the complex molecular structure that causes lethal infections by Mycobacterium tuberculosis (Mtb). Their findings might have implications for potential therapies against antibiotic-resistant tuberculosis.
MediCortex uses crowdfunding to revolutionise brain injury diagnostics
Head trauma is a common injury, and according to several scientific studies, undiagnosed concussion may lead to devastating outcomes and a premature neurodegenerative condition.
Hebrew University launches cannabinoid research centre
The new centre will serve as one of the world’s leading institutes for conducting and coordinating research about cannabinoids, endocannabinoids and medical Cannabis. In addition, it will promote collaboration and disseminate information.
Mini brains from the petri dish
A new method could push research into developmental brain disorders an important step forward.
Diagnosing cancer: new process for identifying biomarkers established
Scientists have established a process for identifying biomarkers for the diagnosis of different types of cancer.
New meningitis bacteria research could hold key to developing improved vaccines
Meningococcal infections are the most common cause of bacterial meningitis in the United Kingdom, a life-threatening disease that poses a continuing threat worldwide. With growing fears around the increase of antibiotic-resistant bacteria, understanding why certain strains don't respond to vaccines could prove vital in helping reduce the number of global…
Stem cell patch shows early promise in treating heart failure
In a Phase I clinical trial, heart failure patients treated with patches made from their muscle cells showed improved exercise capacity and heart function after one year. Stem cell patch-based therapy may be a viable heart failure therapy and should be validated in larger clinical trials, researchers conclude.
Finger prosthesis provides clues to brain health
In a collaboration between Swedish and Italian researchers, the aim was to analyse how the brain interprets information from a virtual experience of touch, created by a finger prosthesis with artificial sensation. The result was – completely unexpectedly – a new method for measuring brain health.
Nimbus Therapeutics enters into strategic partnership with Charles River Laboratories to advance new therapeutic programs
Nimbus Therapeutics and Charles River Laboratories International, Inc. (NYSE: CRL) launched a multi-year strategic partnership to advance new programs spanning the disease areas of immunology, metabolic disorders and oncology from the discovery phase through to Investigational New Drug (IND) submission.
Discovery of ‘mini-brains’ could change understanding of pain medication
The human body’s peripheral nervous system could be capable of interpreting its environment and modulating pain, neuroscientists have established, after successfully studying how rodents reacted to stimulation.